Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

por Conery, Andrew R, Centore, Richard C, Neiss, Adrianne, Keller, Patricia J, Joshi, Shivangi, Spillane, Kerry L, Sandy, Peter, Hatton, Charlie, Pardo, Eneida, Zawadzke, Laura, Bommi-Reddy, Archana, Gascoigne, Karen E, Bryant, Barbara M, Mertz, Jennifer A, Sims, Robert J
Publicado 2016

Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

por Conery, Andrew R, Centore, Richard C, Neiss, Adrianne, Keller, Patricia J, Joshi, Shivangi, Spillane, Kerry L, Sandy, Peter, Hatton, Charlie, Pardo, Eneida, Zawadzke, Laura, Bommi-Reddy, Archana, Gascoigne, Karen E, Bryant, Barbara M, Mertz, Jennifer A, Sims, Robert J
Publicado 2016

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

por Caligiuri, Maureen, Williams, Grace L., Castro, Jennifer, Battalagine, Linda, Wilker, Erik, Yao, Lili, Schiller, Shawn, Toms, Angela, Li, Ping, Pardo, Eneida, Graves, Bradford, Azofeifa, Joey, Chicas, Agustin, Herbertz, Torsten, Lai, Maria, Basken, Joel, Wood, Kenneth W., Xu, Qunli, Guichard, Sylvie M.
Publicado 2023